An 82% objective response rate in previously untreated metastatic pancreatic ductal adenocarcinoma is the kind of number that demands scrutiny, because the disease has historically killed most patients within months of a metastatic diagnosis. Population-level median overall survival for metastatic PDAC sits around 5.4 months, making the efficacy signals Revolution Medicines presented at the ESMO Gastrointestinal Cancers Congress in Munich this week genuinely striking, even at Phase 1/2 scale.
The data come from two separate trials of zoldonrasib, the company’s oral RAS(ON) G12D-selective covalent inhibitor, each targeting a distinct treatment line. In the first-line setting, 41 patients received zoldonrasib plus modified FOLFIRINOX and 40 received it with gemcitabine plus nab-paclitaxel. The mFFX arm produced that 82% ORR alongside a 96% disease control rate. The GnP arm returned a 61% ORR and 90% DCR. Grade 3 or higher treatment-related adverse events ran at 61% and 80% respectively, driven primarily by hematologic toxicity consistent with the chemotherapy backbones rather than a new zoldonrasib-specific signal. Mean dose intensities of 86% and 90% suggest the combination is deliverable without excessive modification pressure. In the second-line cohort of the doublet trial, pairing zoldonrasib with daraxonrasib, Revolution’s multi-selective RAS(ON) inhibitor, produced a 50% ORR, a 97% disease control rate, and a median progression-free survival of 9.6 months. Third-line and beyond patients reached a 47% ORR and a median PFS of 7.6 months. Only 2% discontinued zoldonrasib for toxicity.
The strategic architecture here matters as much as the numbers. Revolution is not running one Phase 3 bet; it is running two simultaneously, each targeting a different position in the RAS G12D treatment sequence. RASolute 305 tests the chemo combination in the first-line setting. The planned RASolute 309 will pit the zoldonrasib-plus-daraxonrasib doublet against gemcitabine and nab-paclitaxel, also in previously untreated patients, despite the Phase 1 data coming from a pretreated population. That extrapolation is a calculated risk. The doublet’s tolerability profile in later-line disease, where Grade 3-plus TRAEs reached only 35%, gives the company reason to believe the combination can hold up in less-treated patients, but it is a hypothesis Phase 3 will need to answer directly. The foundation for that confidence comes partly from daraxonrasib’s Phase 3 RASolute 302 win in second-line PDAC, which established that RAS(ON) inhibition translates into survival benefit in this disease.
The single marker worth tracking now is the RASolute 305 interim analysis timeline. The first-line chemo combination trial is already enrolling, and its ORR data from 81 Phase 1/2 patients is strong enough to raise expectations materially. If interim PFS data in RASolute 305 confirms depth of response translates into durable disease control, Revolution will have reshaped the frontline standard of care conversation for roughly a quarter of all PDAC patients who carry the G12D mutation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
